References
- Mäki M, Lohi O. Coeliac disease. In: Walker , et al., editors. Pediatric gastrointestinal disease. Pathophysiology, diagnosis, management. 4th ed. Hamilton: BC Decker Inc.; 2004. pp 932–43.
- Sollid L. Coeliac disease: dissecting a complex inflammatory disorder. Nature Rev Immuol 2002; 2: 647–55
- Shan L, Molberg O, Parrot I, Hausch F, Filiz F, Gray GM, et al. Structural basis for gluten intolerance in celiac sprue. Science 2002; 297: 2275–9
- Hausch F, Shan L, Santiago NA, Gray GM, Khosla C. Intestinal digestive resistance of immunodominant gliadin peptides. Am J Physiol Gastrointest Liver Physiol 2002; 283: G996–1003
- Matysiak-Budnik T, Candalh C, Cellier C, Dugave C, Namane A, Vidal-Martinez T, et al. Limited efficiency of prolyl-endopeptidase in the detoxification of gliadin peptides in celiac disease. Gastroenterology 2005; 129: 786–96
- Polgár L. The prolyl oligopeptidase family. Cell Mol Life Sci 2002; 59: 349–62
- Matysiak-Budnik T, Candalh C, Dugave C, Namane A, Cellier C, Cerf-Bensussan N, et al. Alterations of the intestinal transport and processing of gliadin peptides in celiac disease. Gastroenterology 2003; 125: 696–707
- Diosdado B, Wapenaar MC, Franke L, Duran KJ, Goerres MJ, Hadithi M, et al. A microarray screen for novel candidate genes in coeliac disease pathogenesis. Gut 2004; 53: 944–51
- Diosdado B, Stepniak DT, Monsuur AJ, Franke L, Wapenaar MC, Mearin ML, et al. No genetic association of the human prolyl endopeptidase gene in the Dutch celiac disease population. Am J Physiol Gastrointest Liver Physiol 2005; 289: G495–500
- Wallén EAA, Christiaans JAM, Forsber MM, Venäläinen JI, Männistö PT, Gynther J. Dicarboxylic acid bis (l-prolyl-pyrrolidine) amides as prolyl oligopeptidase inhibitors. J Med Chem 2002; 45: 4581–4
- Venäläinen JI, Juvonen RO, Forsberg MM, Garcia-Horsman A, Poso A, Wallen EA, et al. Substrate-dependent, non-hyperbolic kinetics of pig brain prolyl oligopeptidase and its tight binding inhibition by JTP-4819. Biochem Pharmacol 2002; 64: 463–71
- Jarho EM, Venäläinen JI, Huuskonen J, Christiaans JA, Garcia-Horsman JA, Forsberg MM, et al. A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors. J Med Chem 2004; 47: 5605–7
- Korponay-Szabo IR, Halttunen T, Szalai Z, Laurila K, Kiraly R, Kovacs JB, et al. In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies. Gut 2004; 53: 641–8
- Schulz I, Zeitschel U, Rudolph T, Ruiz-Carrillo D, Rahfeld JU, Gerhartz B, et al. Subcellular localization suggests novel functions for prolyl endopeptidase in protein secretion. J Neurochem 2005; 94: 970–9
- Jones PE, L'Hirondel CL, Peters TJ. Protein synthesis by cultured jejunal mucosa from control subjects and patients with coeliac disease. Gut 1981; 22: 612–27
- Nakshabendi IM, Downie S, Russell RI, Rennie MJ. Increased rates of duodenal mucosal protein synthesis in vivo in patients with untreated coeliac disease. Gut 1996; 39: 176–9
- Shan L, Mathews II, Khosla C. Structural and mechanistic analysis of two prolyl endopeptidases: role of interdomain dynamics in catalysis and specificity. Proc Natl Acad Sci USA 2005; 102: 3599–604